Publications by authors named "A Tsolakidis"
Increased prevalence of inflammatory arthritis, systemic lupus erythematosus and systemic sclerosis, during 2020-2023 versus 2016-2019 in a Nation-Wide Cohort Study.
Rheumatol Int
December 2024
Article Synopsis
- A study in Greece looked at how common autoimmune rheumatic diseases (ARD) are over time, comparing the years 2016-2019 to 2020-2023, including the effects of the Covid-19 pandemic.* ! -
- The results showed that diseases like Rheumatoid Arthritis and Psoriatic Arthritis became more common during the pandemic period, especially among younger and older adults.* ! -
- There was a big increase in the number of people with these diseases, so Greece will need more resources like doctors and medicine to help all these patients.* !
Background: Drug persistence is a crucial aspect of treatment success in psoriasis.
Objectives: To record real-world evidence concerning drug survival of biologic agents used for psoriasis treatment and to detect associated modifying factors in Greece.
Methods: This was a retrospective cohort study based on data extracted from the nationwide Greek prescription system.
Objectives: This study aimed to investigate the prevalence and incidence of medication-treated diabetes mellitus and the evolving patterns of glucose-lowering treatments the year before and during the first two years of the coronavirus disease 2019 (COVID-19) pandemic.
Methods: Data from the Greek electronic prescription database were analyzed for 2019, 2020, and 2021. The study population included individuals with active social security numbers.
Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database.
Int J Cardiol Cardiovasc Risk Prev
June 2024
Background: Despite recent guidelines appropriate lipid-lowering treatment (LLT) remains suboptimal in everyday clinical practice.
Aims: We aimed to describe clinical practice of use of LLT for at least high CV risk populations in a Hellenic real-world setting and assess how this relates to the European Society of Cardiology treatment guidelines.
Methods: We analyzed data from a retrospective cohort study of the National Registry of patients with dyslipidemia between 1/7/2017 and 30/6/2019 who were at least of high CV risk and filled a dual or triple lipid-lowering treatment (dLLT, tLLT) prescription.